Search tips
Search criteria

Results 1-2 (2)

Clipboard (0)

Select a Filter Below

more »
Year of Publication
Document Types
author:("nicolas, E")
1.  Mesenchymal stem cells from Shwachman–Diamond syndrome patients display normal functions and do not contribute to hematological defects 
Blood Cancer Journal  2012;2(10):e94-.
Shwachman–Diamond syndrome (SDS) is a rare inherited disorder characterized by bone marrow (BM) dysfunction and exocrine pancreatic insufficiency. SDS patients have an increased risk for myelodisplastic syndrome and acute myeloid leukemia. Mesenchymal stem cells (MSCs) are the key component of the hematopoietic microenvironment and are relevant in inducing genetic mutations leading to leukemia. However, their role in SDS is still unexplored. We demonstrated that morphology, growth kinetics and expression of surface markers of MSCs from SDS patients (SDS-MSCs) were similar to normal MSCs. Moreover, SDS-MSCs were able to differentiate into mesengenic lineages and to inhibit the proliferation of mitogen-activated lymphocytes. We demonstrated in an in vitro coculture system that SDS-MSCs, significantly inhibited neutrophil apoptosis probably through interleukin-6 production. In a long-term coculture with CD34+-sorted cells, SDS-MSCs were able to sustain CD34+ cells survival and to preserve their stemness. Finally, SDS-MSCs had normal karyotype and did not show any chromosomal abnormality observed in the hematological components of the BM of SDS patients. Despite their pivotal role in the hematopoietic stem cell niche, our data suggest that MSC themselves do not seem to be responsible for the hematological defects typical of SDS patients.
PMCID: PMC3483621  PMID: 23064742
Shwachman–Diamond syndrome; mesenchymal stem cells; bone marrow failure; SBDS
2.  RES3/417: The Development of a Clinical Trial Web Site: a proposal for a model 
The Internet and the World Wide Web have been recently introduced in the management of some aspects of large scale clinical trials. We have developed a model for a clinical trial Web site in order to enhance communication among people involved in a clinical trial, to disseminate clinical trials information, and to decentralise some trials activities.
One section of the Web site should include general medical information such as summary of the background, aim, design of the ongoing trial and results of similar trials. A directory of investigators, members committees, sponsors and monitors (with their e-mail address) could also help people in improving communication. Another section should include centre based summaries of the trial: randomised patients, follow-up schedule, patients lost to follow-up, outstanding case report forms and queries, and statistics on centres quality are some examples. An additional section should be dealing with the latest trial news: trial newsletter, planned meetings, congresses presentations, archive of frequently asked questions on the application of the trial protocol. Patient randomisation/registration and remote data entry are two additional components of a clinical data management system that could be included in the site. In this case database access rules and security should be implemented. Other Web based applications are related with the supply of study material (protocol, case report forms, informed consent), the management of mailing lists for the investigators, the publishing of sub-analyses results.
Although some problems still exist (Internet connection limitations, security, lack of common standard for client software, personnel training), the Internet and the clinical trial Web sites could in the few years transform the way a clinical trial is conducted.
PMCID: PMC1761829
Clinical Trial; Internet; World Wide Web; Trial Web Site

Results 1-2 (2)